Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Update

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) saw a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 1,290,000 shares, a decline of 20.4% from the August 15th total of 1,620,000 shares. Based on an average daily volume of 531,800 shares, the days-to-cover ratio is currently 2.4 days.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Maxim Group upgraded shares of Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a report on Thursday, July 11th. StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics in a report on Sunday. They issued a “hold” rating on the stock.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC bought a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned 0.12% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Price Performance

Shares of BCLI stock traded down $0.02 during trading hours on Monday, hitting $0.27. The company had a trading volume of 442,645 shares, compared to its average volume of 744,446. The company’s fifty day moving average is $0.33 and its 200 day moving average is $0.42. Brainstorm Cell Therapeutics has a fifty-two week low of $0.13 and a fifty-two week high of $1.08. The stock has a market capitalization of $18.64 million, a PE ratio of -0.83 and a beta of 0.35.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). During the same quarter last year, the business earned ($0.27) earnings per share. Equities analysts forecast that Brainstorm Cell Therapeutics will post -0.19 earnings per share for the current year.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.